A cyclodextrin-based nanoformulation achieves co-delivery of ginsenoside Rg3 and quercetin for chemo-immunotherapy in colorectal cancer

• DOI: 10.1016/j.apsb.2021.06.005
• Publication Date: 2021-06-18T07:51:25Z
• Authors: Dandan Sun; Yifang Zou; Liu Song; Shulan Han; Hao Yang; Di Chu; Yun Dai; Jie Ma; Caitriona M. O'Dr...; Zhuo Yu; Jianfeng Guo
• Keywords: Cancer Immunotherapy

The immune checkpoint blockade therapy has profoundly revolutionized the field of cancer immunotherapy. However, despite great promise for a variety cancers, efficacy inhibitors is still low in colorectal (CRC). This mainly due to immunosuppressive feature tumor microenvironment (TME). Emerging evidence reveals that certain chemotherapeutic drugs induce immunogenic cell death (ICD), demonstrating potential remodeling TME. In this study, ginsenoside Rg3 (Rg3) as an ICD inducer against CRC cells was confirmed using